SCHEMBL5536890

SCHEMBL5536890

CC(C)(C)[Si](C)(C)OCCCC(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
TP53 P04637 1/20 0.40
DUT P33316 2/20 0.38
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8030008 0.93 ALDH1A1 (0.44) ALDH1A1TP53DUTTSHR
SCHEMBL10702400 0.88 TSHR (0.36) ALDH1A1TP53DUTTSHR
SCHEMBL4590603 0.82 ALDH1A1 (0.41) ALDH1A1DUTTSHR
SCHEMBL875754 0.82 DUT (0.39) ALDH1A1DUT
SCHEMBL28516260 0.82 DUT (0.39) TP53DUT
SCHEMBL7484513 0.81 DUT (0.38) DUT
SCHEMBL28915925 0.79 ALDH1A1 (0.46) ALDH1A1TP53TSHR
Lithium Ion SCHEMBL15778648 0.79 CA1 (0.38) DUT
SCHEMBL19543597 0.79 DUT (0.37) DUT
SCHEMBL11635954 0.79 TSHR (0.50) ALDH1A1DUTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115353475-B Preparation method of levetiracetam 浙江京新药业股份有限公司 2024-04-26 CN disclosed
CN-115353475-A Preparation method of levetiracetam 浙江京新药业股份有限公司 2022-11-18 CN disclosed
US-20070276142-A1 Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds CHEMINOVA A/S (DK) 2007-11-29 US disclosed
EP-1716088-A1 CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE ALPHA-HALO-CAR BONYL COMPOUNDS Cheminova A/S (DK) 2006-11-02 EP disclosed
WO-2005080298-A1 CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE α-HALO-CARBONYL COMPOUNDS CHEMINOVA A/S (DK) 2005-09-01 WO disclosed
US-5248830-A Enantioselective preparation of acetylenic or olefinic substituted cycloalkenyl dihydroxybutyrates and 4-hydroxy-tetrahydro-pyran-2-ones RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1993-09-28 US disclosed
WO-1992014692-A1 ENANTIOSELECTIVE PREPARATION OF ACETYLENIC OR OLEFINIC SUBSTITUTED CYCLOALKENYL DIHYDROXYBUTYRATES AND 4-HYDROXY-TETRAHYDROPYRAN-2-ONES RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276142-A1 Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds CBR1, CBR3, HAO1 ALDH1A1 762/4885TP53 3461/4885DUT 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.